| | - Fourth-quarter reported sales increased 1.5 percent; organic sales growth for the underlying base business increased 11.0 percent
- Full-year 2023 reported sales decreased 8.1 percent due to anticipated decline in COVID-19 testing-related sales; organic sales growth for the underlying base business increased 11.6 percent
- Full-year 2023 GAAP diluted EPS of $3.26; adjusted diluted EPS of $4.44
- R&D pipeline continues to deliver steady cadence of new products
ABBOTT PARK, Ill., Jan. 24, 2024 /PRNewswire/ -- Abbott today announced financial results for the fourth quarter ended Dec. 31, 2023. - Fourth-quarter sales increased 1.5 percent on a reported basis, 2.1 percent on an organic basis, and 11.0 percent on an organic basis, excluding COVID-19 testing-related sales1.
- Fourth-quarter GAAP diluted EPS of $0.91 and adjusted diluted EPS of $1.19, which excludes specified items.
- Abbott issues full-year 2024 guidance for diluted EPS on a GAAP basis of $3.20 to $3.40 and full-year adjusted diluted EPS of $4.50 to $4.70.
- Abbott projects full-year 2024 organic sales growth, excluding COVID-19 testing-related sales, to be in the range of 8.0% to 10.0%2.
- In 2023, Abbott continued to recapture market share in the U.S. infant formula market. The company has now reclaimed its previous market-leading position, as measured on a volume basis.
- In December, Abbott announced U.S. Food and Drug Administration (FDA) approval of its new laboratory automation system, GLP systems Track™, to help laboratories optimize performance and safety to better meet the growing demand for diagnostic testing.
- In January, Abbott announced that the first-in-human procedures were conducted using the company’s new Volt™ Pulsed Field Ablation (PFA) System to treat patients with heart rhythm disorders such as atrial fibrillation (AFib). These procedures were part of Abbott’s Volt CE Mark clinical study. Abbott anticipates approval for its U.S. clinical trial (IDE) for the Volt PFA System in the first half of 2024.
- In January, Abbott announced that Tandem Diabetes Care’s t:slim X2™3 insulin pump is the first automated insulin delivery system in the U.S. to integrate with Abbott’s new FreeStyle Libre® 2 Plus sensor.
“The strength and diversity of the Abbott portfolio drove our success in 2023,” said Robert B. Ford, chairman and chief executive officer, Abbott. “We’re entering 2024 with a lot of positive momentum, and with our highly productive pipeline, we’re well-positioned for growth in 2024 and beyond.” FOURTH-QUARTER BUSINESS OVERVIEW
Management believes that measuring sales growth rates on an organic basis, which excludes the impact of foreign exchange, the impact of exiting the pediatric nutrition business in China, and the impact of the acquisition of Cardiovascular Systems, Inc. (CSI), is an appropriate way for investors to best understand the core underlying performance of the business. Management further believes that measuring sales growth rates on an organic basis excluding COVID-19 tests is an appropriate way for investors to best understand underlying base business performance as the COVID-19 pandemic has shifted to an endemic state, resulting in significantly lower demand for COVID-19 tests. Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates. | Fourth Quarter 2023 Results (4Q23) | | | | Sales 4Q23 ($ in millions) | Total Company | | Nutrition | | Diagnostics | | Established
Pharmaceuticals | | Medical Devices | | U.S. | 3,949 | | 860 | | 1,020 | | — | | 2,065 | | International | 6,292 | | 1,178 | | 1,514 | | 1,222 | | 2,378 | | Total reported | 10,241 | | 2,038 | | 2,534 | | 1,222 | | 4,443 | | | | | | | | | | | | | % Change vs. 4Q22 | | | | | | | | | | | U.S. | (6.4) | | 8.2 | | (38.8) | | n/a | | 17.6 | | International | 7.2 | | 15.3 | | (6.0) | | 0.5 | | 17.5 | | Total reported | 1.5 | | 12.2 | | (22.7) | | 0.5 | | 17.5 | | Impact of foreign exchange | (0.8) | | (0.7) | | (0.4) | | (8.3) | | 1.0 | | Impact of CSI acquisition | 0.4 | | — | | — | | — | | 1.1 | | Impact of business exit | (0.2) | | (1.0) | | — | | — | | — | | Organic | 2.1 | | 13.9 | | (22.3) | | 8.8 | | 15.4 | | Impact of COVID-19 testing sales (4) | (8.9) | | — | | (24.5) | | — | | — | | Organic (excluding COVID-19 tests) | 11.0 | | 13.9 | | 2.2 | | 8.8 | | 15.4 | | | | | | | | | | | | | U.S. | 7.1 | | 8.2 | | (10.7) | | n/a | | 15.5 | | International | 13.4 | | 18.5 | | 10.9 | | 8.8 | | 15.4 | | Full-Year 2023 Results (12M23) | | | | Sales 12M23 ($ in millions) | Total Company | | Nutrition | | Diagnostics | | Established
Pharmaceuticals | | Medical Devices | | U.S. | 15,452 | | 3,413 | | 4,329 | | — | | 7,696 | | International | 24,657 | | 4,741 | | 5,659 | | 5,066 | | 9,191 | | Total reported | 40,109 | | 8,154 | | 9,988 | | 5,066 | | 16,887 | | | | | | | | | | | | | % Change vs. 12M22 | | | | | | | | | | | U.S. | (14.8) | | 16.9 | | (49.3) | | n/a | | 15.2 | | International | (3.3) | | 4.4 | | (28.7) | | 3.1 | | 13.2 | | Total reported | (8.1) | | 9.3 | | (39.4) | | 3.1 | | 14.1 | | Impact of foreign exchange | (2.0) | | (2.3) | | (1.2) | | (7.8) | | (1.0) | | Impact of CSI acquisition | 0.3 | | — | | — | | — | | 0.9 | | Impact of business exit | (0.2) | | (1.4) | | — | | — | | — | | Organic | (6.2) | | 13.0 | | (38.2) | | 10.9 | | 14.2 | | Impact of COVID-19 testing sales (4) | (17.8) | | — | | (44.0) | | — | | — | | Organic (excluding COVID-19 tests) | 11.6 | | 13.0 | | 5.8 | | 10.9 | | 14.2 | | | | | | | | | | | | | U.S. | 11.3 | | 16.9 | | 1.3 | | n/a | | 13.3 | | International | 11.7 | | 10.4 | | 8.5 | | 10.9 | | 14.9 | Refer to table titled “Non-GAAP Revenue Reconciliation” for a reconciliation of adjusted historical revenue to reported revenue. | Nutrition | | | | Fourth Quarter 2023 Results (4Q23) | | | | Sales 4Q23 ($ in millions) | Total | | Pediatric | | Adult | | U.S. | 860 | | 505 | | 355 | | International | 1,178 | | 480 | | 698 | | Total reported | 2,038 | | 985 | | 1,053 | | | | | | | | | % Change vs. 4Q22 | | | | | | | U.S. | 8.2 | | 11.4 | | 4.0 | | International | 15.3 | | 12.3 | | 17.4 | | Total reported | 12.2 | | 11.8 | | 12.5 | | Impact of foreign exchange | (0.7) | | (0.5) | | (0.9) | | Impact of business exit | (1.0) | | (2.2) | | — | | Organic | 13.9 | | 14.5 | | 13.4 | | | | | | | | | U.S. | 8.2 | | 11.4 | | 4.0 | | International | 18.5 | | 17.9 | | 18.9 | Worldwide Nutrition sales increased 12.2 percent on a reported basis and 13.9 percent on an organic basis in the fourth quarter. Refer to table titled “Non-GAAP Revenue Reconciliation” for a reconciliation of adjusted historical revenue to reported revenue. In Pediatric Nutrition, global sales increased 11.8 percent on a reported basis and 14.5 percent on an organic basis. International sales increased 12.3 percent on a reported basis and 17.9 percent on an organic basis, which was led by strong growth in Canada and several countries in Latin America. In the U.S., sales growth of 11.4 percent was primarily driven by market share recovery in the infant formula business following a voluntary recall of certain products last year. In Adult Nutrition, global sales increased 12.5 percent on a reported basis and 13.4 percent on an organic basis, which was led by strong global growth of Ensure®, Abbott’s market-leading complete and balanced nutrition brand. | Full-Year 2023 Results (12M23) | | | | Sales 12M23 ($ in millions) | Total | | Pediatric | | Adult | | U.S. | 3,413 | | 1,977 | | 1,436 | | International | 4,741 | | 1,957 | | 2,784 | | Total reported | 8,154 | | 3,934 | | 4,220 | | | | | | | | | % Change vs. 12M22 | | | | | | | U.S. | 16.9 | | 26.6 | | 5.8 | | International | 4.4 | | 2.0 | | 6.2 | | Total reported | 9.3 | | 13.0 | | 6.1 | | Impact of foreign exchange | (2.3) | | (1.8) | | (2.7) | | Impact of business exit | (1.4) | | (3.1) | | — | | Organic | 13.0 | | 17.9 | | 8.8 | | | | | | | | | U.S. | 16.9 | | 26.6 | | 5.8 | | International | 10.4 | | 10.3 | | 10.4 | | Diagnostics | | | | Fourth Quarter 2023 Results (4Q23) | | | | Sales 4Q23 ($ in millions) | Total | | Core Laboratory | | Molecular | | Point of Care | | Rapid
Diagnostics * | | U.S. | 1,020 | | 326 | | 44 | | 107 | | 543 | | International | 1,514 | | 1,044 | | 109 | | 42 | | 319 | | Total reported | 2,534 | | 1,370 | | 153 | | 149 | | 862 | | | | | | | | | | | | | % Change vs. 4Q22 | | | | | | | | | | | U.S. | (38.8) | | 8.3 | | (27.7) | | 20.7 | | (55.3) | | International | (6.0) | | 8.4 | | (7.8) | | (1.0) | | (34.4) | | Total reported | (22.7) | | 8.4 | | (14.6) | | 13.6 | | (49.3) | | Impact of foreign exchange | (0.4) | | (0.7) | | 0.3 | | 0.6 | | (0.1) | | Organic | (22.3) | | 9.1 | | (14.9) | | 13.0 | | (49.2) | | Impact of COVID-19 testing sales (4) | (24.5) | | (0.6) | | (16.6) | | — | | (35.5) | | Organic (excluding COVID-19 tests) | 2.2 | | 9.7 | | 1.7 | | 13.0 | | (13.7) | | | | | | | | | | | | | U.S. | (10.7) | | 8.8 | | (12.6) | | 20.7 | | (29.2) | | International | 10.9 | | 10.0 | | 8.2 | | (2.9) | | 18.6 | As expected, Diagnostics sales growth in the fourth quarter was negatively impacted by year-over-year declines in COVID-19 testing-related sales4. Worldwide COVID-19 testing sales were $288 million in the fourth quarter of 2023 compared to $1.069 billion in the fourth quarter of the prior year. Excluding COVID-19 testing-related sales, global Diagnostics sales increased 1.7 percent on a reported basis and 2.2 percent on an organic basis. | Full-Year 2023 Results (12M23) | | | | Sales 12M23 ($ in millions) | Total | | Core Laboratory | | Molecular | | Point of Care | | Rapid
Diagnostics * | | U.S. | 4,329 | | 1,243 | | 172 | | 396 | | 2,518 | | International | 5,659 | | 3,916 | | 402 | | 169 | | 1,172 | | Total reported | 9,988 | | 5,159 | | 574 | | 565 | | 3,690 | | | | | | | | | | | | | % Change vs. 12M22 | | | | | | | | | | | U.S. | (49.3) | | 9.3 | | (53.6) | | 6.4 | | (62.1) | | International | (28.7) | | 4.4 | | (35.7) | | 10.3 | | (65.6) | | Total reported | (39.4) | | 5.5 | | (42.3) | | 7.5 | | (63.3) | | Impact of foreign exchange | (1.2) | | (2.9) | | (0.7) | | (0.2) | | (0.4) | | Organic | (38.2) | | 8.4 | | (41.6) | | 7.7 | | (62.9) | | Impact of COVID-19 testing sales (4) | (44.0) | | (1.0) | | (33.5) | | — | | (64.2) | | Organic (excluding COVID-19 tests) | 5.8 | | 9.4 | | (8.1) | | 7.7 | | 1.3 | | | | | | | | | | | | | U.S. | 1.3 | | 10.1 | | (17.8) | | 6.4 | | (4.8) | | International | 8.5 | | 9.1 | | (3.8) | | 10.8 | | 11.6 | | | | *The Acelis Connected Health business was internally transferred from Rapid Diagnostics to Heart Failure on January 1, 2023. As a result, $28 million of sales in the fourth quarter of 2022 and $115 million in the full-year 2022 were moved from Rapid Diagnostics to Heart Failure. | | | | Established Pharmaceuticals | | | | Fourth Quarter 2023 Results (4Q23) | | | | Sales 4Q23 ($ in millions) | Total | | Key Emerging
Markets | | Other | | U.S. | — | | — | | — | | International | 1,222 | | 918 | | 304 | | Total reported | 1,222 | | 918 | | 304 | | | | | | | | | % Change vs. 4Q22 | | | | | | | U.S. | n/a | | n/a | | n/a | | International | 0.5 | | 0.5 | | 0.4 | | Total reported | 0.5 | | 0.5 | | 0.4 | | Impact of foreign exchange | (8.3) | | (10.9) | | (0.4) | | Organic | 8.8 | | 11.4 | | 0.8 | | | | | | | | | U.S. | n/a | | n/a | | n/a | | International | 8.8 | | 11.4 | | 0.8 | Established Pharmaceuticals sales increased 0.5 percent on a reported basis and 8.8 percent on an organic basis in the fourth quarter. Key Emerging Markets include several emerging countries that represent the most attractive long-term growth opportunities for Abbott’s branded generics product portfolio. Sales in these geographies increased 0.5 percent on a reported basis and increased 11.4 percent on an organic basis, led by growth in several geographies and therapeutic areas, including cardiometabolic, gastroenterology, respiratory, and central nervous system/pain management. | Full-Year 2023 Results (12M23) | | | | Sales 12M23 ($ in millions) | Total | | Key Emerging
Markets | | Other | | U.S. | — | | — | | — | | International | 5,066 | | 3,807 | | 1,259 | | Total reported | 5,066 | | 3,807 | | 1,259 | | | | | | | | | % Change vs. 12M22 | | | | | | | U.S. | n/a | | n/a | | n/a | | International | 3.1 | | 1.1 | | 9.8 | | Total reported | 3.1 | | 1.1 | | 9.8 | | Impact of foreign exchange | (7.8) | | (9.2) | | (3.0) | | Organic | 10.9 | | 10.3 | | 12.8 | | | | | | | | | U.S. | n/a | | n/a | | n/a | | International | 10.9 | | 10.3 | | 12.8 | | Medical Devices | | | | Fourth Quarter 2023 Results (4Q23) | | | | Sales 4Q23 ($ in millions) | Total | | Rhythm
Management | | Electro- physiology | | Heart
Failure * | | Vascular | | Structural
Heart | | Neuro-
modulation | | Diabetes
Care | | U.S. | 2,065 | | 285 | | 279 | | 227 | | 245 | | 231 | | 197 | | 601 | | International | 2,378 | | 297 | | 314 | | 74 | | 432 | | 267 | | 43 | | 951 | | Total reported | 4,443 | | 582 | | 593 | | 301 | | 677 | | 498 | | 240 | | 1,552 | | | | | | | | | | | | | | | | | | | % Change vs. 4Q22 | | | | | | | | | | | | | | | | | U.S. | 17.6 | | 12.0 | | 15.0 | | 13.6 | | 14.8 | | 7.9 | | 20.8 | | 28.3 | | International | 17.5 | | 14.5 | | 28.0 | | 26.6 | | 10.4 | | 17.6 | | 10.2 | | 18.4 | | Total reported | 17.5 | | 13.3 | | 21.5 | | 16.6 | | 12.0 | | 12.9 | | 18.8 | | 22.0 | | Impact of foreign exchange | 1.0 | | 1.2 | | 0.3 | | 1.2 | | 1.1 | | 1.5 | | — | | 1.3 | | Impact of CSI acquisition | 1.1 | | — | | — | | — | | 6.4 | | — | | — | | — | | Organic | 15.4 | | 12.1 | | 21.2 | | 15.4 | | 4.5 | | 11.4 | | 18.8 | | 20.7 | | | | | | | | | | | | | | | | | | | U.S. | 15.5 | | 12.0 | | 15.0 | | 13.6 | | (2.5) | | 7.9 | | 20.8 | | 28.3 | | International | 15.4 | | 12.1 | | 27.3 | | 21.4 | | 8.3 | | 14.7 | | 10.2 | | 16.2 | Worldwide Medical Devices sales increased 17.5 percent on a reported basis and 15.4 percent on an organic basis in the fourth quarter. Sales growth was led by double-digit organic growth in Diabetes Care, Neuromodulation, Structural Heart, Electrophysiology, Heart Failure, and Rhythm Management. Several recently launched products and new indications contributed to the strong performance, including Amplatzer®, Amulet®, Navitor®, TriClip®, and AVEIR®. In Electrophysiology, internationally, sales grew more than 25.0 percent on a reported and organic basis, which included sales growth of more than 20.0 percent in Europe. In Diabetes Care, FreeStyle Libre sales were $1.4 billion, which represents sales growth of 25.5 percent on a reported basis and 23.8 percent on an organic basis. | Full-Year 2023 Results (12M23) | | | | Sales 12M23 ($ in millions) | Total | | Rhythm
Management | | Electro- physiology | | Heart
Failure * | | Vascular | | Structural
Heart | | Neuro-
modulation | | Diabetes
Care | | U.S. | 7,696 | | 1,085 | | 1,008 | | 888 | | 978 | | 883 | | 725 | | 2,129 | | International | 9,191 | | 1,170 | | 1,187 | | 273 | | 1,703 | | 1,061 | | 165 | | 3,632 | | Total reported | 16,887 | | 2,255 | | 2,195 | | 1,161 | | 2,681 | | 1,944 | | 890 | | 5,761 | | | | | | | | | | | | | | | | | | | % Change vs. 12M22 | | | | | | | | | | | | | | | | | U.S. | 15.2 | | 5.5 | | 10.8 | | 9.6 | | 13.2 | | 7.9 | | 17.2 | | 30.3 | | International | 13.2 | | 7.4 | | 16.6 | | 21.1 | | 5.2 | | 18.7 | | 9.0 | | 16.3 | | Total reported | 14.1 | | 6.5 | | 13.9 | | 12.1 | | 8.0 | | 13.6 | | 15.5 | | 21.1 | | Impact of foreign exchange | (1.0) | | (1.0) | | (2.0) | | 0.1 | | (1.3) | | (0.7) | | (0.9) | | (0.8) | | Impact of CSI acquisition | 0.9 | | — | | — | | — | | 5.3 | | — | | — | | — | | Organic | 14.2 | | 7.5 | | 15.9 | | 12.0 | | 4.0 | | 14.3 | | 16.4 | | 21.9 | | | | | | | | | | | | | | | | | | | U.S. | 13.3 | | 5.5 | | 10.8 | | 9.6 | | (1.0) | | 7.9 | | 17.2 | | 30.3 | | International | 14.9 | | 9.4 | | 20.5 | | 20.5 | | 6.7 | | 20.1 | | 13.1 | | 17.5 | | | | *The Acelis Connected Health business was internally transferred from Rapid Diagnostics to Heart Failure on January 1, 2023. As a result, $28 million of sales in the fourth quarter of 2022 and $115 million in the full-year 2022 were moved from Rapid Diagnostics to Heart Failure. | ABBOTT’S EARNINGS-PER-SHARE GUIDANCE
Abbott projects full-year 2024 diluted earnings per share under GAAP of $3.20 to $3.40. Abbott forecasts specified items for the full-year 2024 of $1.30 per share primarily related to intangible amortization, costs associated with acquisitions, restructuring and cost reduction initiatives and other net expenses. Excluding specified items, projected adjusted diluted earnings per share would be $4.50 to $4.70 for the full-year 2024. ABBOTT DECLARES 400TH CONSECUTIVE QUARTERLY DIVIDEND
On Dec. 15, 2023, the board of directors of Abbott declared the company’s quarterly dividend of $0.55 per share. Abbott’s cash dividend is payable Feb. 15, 2024, to shareholders of record at the close of business on Jan. 12, 2024. Abbott has increased its dividend payout for 52 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years. About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 114,000 colleagues serve people in more than 160 countries. Connect with us at www.abbott.com, on LinkedIn at www.linkedin.com/company/abbott-/, on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews. Abbott will live-webcast its fourth-quarter earnings conference call through its Investor Relations website at www.abbottinvestor.com at 8 a.m. Central time today. An archived edition of the webcast will be available later in the day. — Private Securities Litigation Reform Act of 1995 —
A Caution Concerning Forward-Looking Statements Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2022, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law. | 1 | In the fourth quarter of 2023, total worldwide sales were $10.241 billion and COVID-19 testing-related sales were $288 million. In the fourth quarter of 2022, total worldwide sales were $10.091 billion and COVID-19 testing-related sales were $1.069 billion. | | | | | 2 | Abbott has not provided the related GAAP financial measure for organic sales growth, excluding COVID-19 testing-related sales, on a forward-looking basis because the company is unable to predict with reasonable certainty the impact of foreign exchange due to the unpredictability of future changes in foreign exchange rates, which could significantly impact reported sales growth. In addition, as the COVID-19 pandemic has shifted to an endemic state, the company has determined that it is unable to predict with reasonable certainty future COVID-19 test sales due to the unpredictability of demand for Covid-19 tests. | | | | | 3 | t:slimX2™ is a trademark of Tandem Diabetes Care, Inc. | | | | | 4 | Diagnostic sales and COVID-19 testing-related sales in 2023 and 2022 are summarized below: | | | | | | Sales 4Q23 | | | COVID Tests Sales 4Q23 | | | ($ in millions) | U.S. | | Int’l | | Total | | | U.S. | | Int’l | | Total | | | Total Diagnostics | 1,020 | | 1,514 | | 2,534 | | | 224 | | 64 | | 288 | | | Core Laboratory | 326 | | 1,044 | | 1,370 | | | 1 | | 3 | | 4 | | | Molecular | 44 | | 109 | | 153 | | | 5 | | 2 | | 7 | | | Rapid Diagnostics | 543 | | 319 | | 862 | | | 218 | | 59 | | 277 | | | | | | | | | | | | | | | | | | | Sales 4Q22 | | | COVID Tests Sales 4Q22 | | | ($ in millions) | U.S. | | Int’l | | Total | | | U.S. | | Int’l | | Total | | | Total Diagnostics | 1,667 | | 1,610 | | 3,277 | | | 776 | | 293 | | 1,069 | | | Core Laboratory | 301 | | 963 | | 1,264 | | | 3 | | 7 | | 10 | | | Molecular | 62 | | 118 | | 180 | | | 17 | | 20 | | 37 | | | Rapid Diagnostics | 1,216 | | 486 | | 1,702 | | | 756 | | 266 | | 1,022 | | | | | | | | | | | | | | | | | | Sales 12M23 | | | COVID Tests Sales 12M23 | | | ($ in millions) | U.S. | | Int’l | | Total | | | U.S. | | Int’l | | Total | | | Total Diagnostics | 4,329 | | 5,659 | | 9,988 | | | 1,255 | | 331 | | 1,586 | | | Core Laboratory | 1,243 | | 3,916 | | 5,159 | | | 7 | | 13 | | 20 | | | Molecular | 172 | | 402 | | 574 | | | 24 | | 19 | | 43 | | | Rapid Diagnostics | 2,518 | | 1,172 | | 3,690 | | | 1,224 | | 299 | | 1,523 | | | | | | | | | | | | | | | | | | | Sales 12M22 | | | COVID Tests Sales 12M22 | | | ($ in millions) | U.S. | | Int’l | | Total | | | U.S. | | Int’l | | Total | | | Total Diagnostics | 8,531 | | 7,938 | | 16,469 | | | 5,498 | | 2,870 | | 8,368 | | | Core Laboratory | 1,137 | | 3,751 | | 4,888 | | | 16 | | 46 | | 62 | | | Molecular | 370 | | 625 | | 995 | | | 190 | | 221 | | 411 | | | Rapid Diagnostics | 6,652 | | 3,409 | | 10,061 | | | 5,292 | | 2,603 | | 7,895 | | | Abbott Laboratories and Subsidiaries Condensed Consolidated Statement of Earnings Fourth Quarter Ended December 31, 2023 and 2022 (in millions, except per share data) (unaudited) | | | | | | | 4Q23 | | 4Q22 | | % Change | | | Net Sales | $10,241 | | $10,091 | | 1.5 | | | | | | | | | | | Cost of products sold, excluding amortization expense | 4,556 | | 4,593 | | (0.8) | | | Amortization of intangible assets | 481 | | 496 | | (3.1) | | | Research and development | 700 | | 725 | | (3.6) | | | Selling, general, and administrative | 2,724 | | 2,973 | | (8.3) | | | Total Operating Cost and Expenses | 8,461 | | 8,787 | | (3.7) | | | | | | | | | | | Operating Earnings | 1,780 | | 1,304 | | 36.5 | | | | | | | | | | | Interest expense, net | 70 | | 66 | | 5.9 | | | Net foreign exchange (gain) loss | 24 | | (14) | | n/m | | | Other (income) expense, net | (109) | | (68) | | 60.9 | | | Earnings before taxes | 1,795 | | 1,320 | | 36.0 | | | Taxes on earnings | 201 | | 287 | | (29.6) | | | | | | | | | | | Net Earnings | $1,594 | | $1,033 | | 54.2 | | | | | | | | | | | Net Earnings excluding Specified Items, as described below | $2,094 | | $1,811 | | 15.6 | 1) | | | | | | | | | | Diluted Earnings per Common Share | $0.91 | | $0.59 | | 54.2 | | | | | | | | | | | Diluted Earnings per Common Share, excluding Specified Items, as described below | $1.19 | | $1.03 | | 15.5 | 1) | | | | | | | | | | Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options | 1,748 | | 1,754 | | | | | | | NOTES: | | See table tilted “Non-GAAP Reconciliation of Financial Information” for an explanation of certain non-GAAP financial information. | | n/m = Percent change is not meaningful. | | See footnotes on the following section. | | | | | 1) | 2023 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $500 million, or $0.28 per share, for intangible amortization, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions and other net expenses. | | | | | | 2022 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $778 million, or $0.44 per share, for intangible amortization, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions, and other net expenses. | | Abbott Laboratories and Subsidiaries Condensed Consolidated Statement of Earnings Twelve Months Ended December 31, 2023 and 2022 (in millions, except per share data) (unaudited) | | | | | | | 12M23 | | 12M22 | | % Change | | | Net Sales | $40,109 | | $43,653 | | (8.1) | | | | | | | | | | | Cost of products sold, excluding amortization expense | 17,975 | | 19,142 | | (6.1) | | | Amortization of intangible assets | 1,966 | | 2,013 | | (2.3) | | | Research and development | 2,741 | | 2,888 | | (5.1) | | | Selling, general, and administrative | 10,949 | | 11,248 | | (2.7) | | | Total Operating Cost and Expenses | 33,631 | | 35,291 | | (4.7) | | | | | | | | | | | Operating Earnings | 6,478 | | 8,362 | | (22.5) | | | | | | | | | | | Interest expense, net | 252 | | 375 | | (33.0) | | | Net foreign exchange (gain) loss | 41 | | 2 | | n/m | | | Other (income) expense, net | (479) | | (321) | | 49.3 | | | Earnings before taxes | 6,664 | | 8,306 | | (19.8) | | | Taxes on earnings | 941 | | 1,373 | | (31.4) | 1) | | | | | | | | | | Net Earnings | $5,723 | | $6,933 | | (17.5) | | | | | | | | | | | Net Earnings excluding Specified Items, as described below | $7,802 | | $9,466 | | (17.6) | 2) | | | | | | | | | | Diluted Earnings per Common Share | $3.26 | | $3.91 | | (16.6) | | | | | | | | | | | Diluted Earnings per Common Share, excluding Specified Items, as described below | $4.44 | | $5.34 | | (16.9) | 2) | | | | | | | | | | Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options | 1,749 | | 1,764 | | | | | | | NOTES: | | See table tilted “Non-GAAP Reconciliation of Financial Information” for an explanation of certain non-GAAP financial information. | | n/m = Percent change is not meaningful. | | See footnotes on the following section. | | | | | 1) | Taxes on Earnings includes the recognition of approximately $22 million and $43 million of excess tax benefits associated with share-based compensation in 2023 and 2022, respectively. | | | | | 2) | 2023 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $2.079 billion, or $1.18 per share, for intangible amortization, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions and other net expenses. | | | | | | 2022 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $2.533 billion, or $1.43 per share, for intangible amortization, charges related to a voluntary recall and restructuring actions, the impairment of R&D intangible assets, acquisition-related costs and other net expenses. | | Abbott Laboratories and Subsidiaries Non-GAAP Reconciliation of Financial Information Fourth Quarter Ended December 31, 2023 and 2022 (in millions, except per share data) (unaudited) | | | | | 4Q23 | | | As Reported
(GAAP) | | Specified
Items | | As Adjusted | | | | | | | | | Intangible Amortization | $ 481 | | $ (481) | | $ — | | Gross Margin | 5,204 | | 518 | | 5,722 | | R&D | 700 | | (78) | | 622 | | SG&A | 2,724 | | (35) | | 2,689 | | Other (income) expense, net | (109) | | (9) | | (118) | | Earnings before taxes | 1,795 | | 640 | | 2,435 | | Taxes on Earnings | 201 | | 140 | | 341 | | Net Earnings | 1,594 | | 500 | | 2,094 | | Diluted Earnings per Share | $ 0.91 | | $ 0.28 | | $ 1.19 | Specified items reflect intangible amortization expense of $481 million and other net expenses of $159 million associated with restructuring actions, costs associated with acquisitions and other net expenses. See table titled “Details of Specified Items” for additional details regarding specified items. | | 4Q22 | | | As Reported
(GAAP) | | Specified
Items | | As Adjusted | | | | | | | | | Intangible Amortization | $ 496 | | $ (496) | | $ — | | Gross Margin | 5,002 | | 612 | | 5,614 | | R&D | 725 | | (71) | | 654 | | SG&A | 2,973 | | (144) | | 2,829 | | Other (income) expense, net | (68) | | (24) | | (92) | | Earnings before taxes | 1,320 | | 851 | | 2,171 | | Taxes on Earnings | 287 | | 73 | | 360 | | Net Earnings | 1,033 | | 778 | | 1,811 | | Diluted Earnings per Share | $ 0.59 | | $ 0.44 | | $ 1.03 | Specified items reflect intangible amortization expense of $496 million and other net expenses of $355 million associated with restructuring actions, costs associated with acquisitions and other expenses. See table titled “Details of Specified Items” for additional details regarding specified items. | Abbott Laboratories and Subsidiaries Non-GAAP Reconciliation of Financial Information Twelve Months Ended December 31, 2023 and 2022 (in millions, except per share data) (unaudited) | | | | | 12M23 | | | As Reported
(GAAP) | | Specified
Items | | As Adjusted | | | | | | | | | Intangible Amortization | $ 1,966 | | $ (1,966) | | $ — | | Gross Margin | 20,168 | | 2,109 | | 22,277 | | R&D | 2,741 | | (222) | | 2,519 | | SG&A | 10,949 | | (102) | | 10,847 | | Other (income) expense, net | (479) | | 25 | | (454) | | Earnings before taxes | 6,664 | | 2,408 | | 9,072 | | Taxes on Earnings | 941 | | 329 | | 1,270 | | Net Earnings | 5,723 | | 2,079 | | 7,802 | | Diluted Earnings per Share | $ 3.26 | | $ 1.18 | | $ 4.44 | Specified items reflect intangible amortization expense of $1.966 billion and other net expenses of $442 million associated with restructuring actions, costs associated with acquisitions and other expenses. See table titled “Details of Specified Items” for additional details regarding specified items. | | 12M22 | | | As Reported
(GAAP) | | Specified
Items | | As Adjusted | | | | | | | | | Intangible Amortization | $ 2,013 | | $ (2,013) | | $ — | | Gross Margin | 22,498 | | 2,351 | | 24,849 | | R&D | 2,888 | | (282) | | 2,606 | | SG&A | 11,248 | | (236) | | 11,012 | | Other (income) expense, net | (321) | | (55) | | (376) | | Earnings before taxes | 8,306 | | 2,924 | | 11,230 | | Taxes on Earnings | 1,373 | | 391 | | 1,764 | | Net Earnings | 6,933 | | 2,533 | | 9,466 | | Diluted Earnings per Share | $ 3.91 | | $ 1.43 | | $ 5.34 | Specified items reflect intangible amortization expense of $2.013 billion and other net expenses of $911 million that includes charges for the impairment of R&D intangible assets, costs associated with a product recall and restructuring actions, acquisition-related costs, and other net expenses. See table titled “Details of Specified Items” for additional details regarding specified items. A reconciliation of the fourth-quarter tax rates for 2023 and 2022 is shown below: | | 4Q23 | | | ($ in millions) | Pre-Tax Income | | Taxes on Earnings | | Tax Rate | | | As reported (GAAP) | $ 1,795 | | $ 201 | | 11.2 % | | | Specified items | 640 | | 140 | | | | | Excluding specified items | $ 2,435 | | $ 341 | | 14.0 % | | | | | | | | | | | | 4Q22 | | | ($ in millions) | Pre-Tax Income | | Taxes on Earnings | | Tax Rate | | | As reported (GAAP) | $ 1,320 | | $ 287 | | 21.7 % | | | Specified items | 851 | | 73 | | | | | Excluding specified items | $ 2,171 | | $ 360 | | 16.5 % | | A reconciliation of the year-to-date tax rates for 2023 and 2022 is shown below: | | 12M23 | | | ($ in millions) | Pre-Tax Income | | Taxes on Earnings | | Tax Rate | | | As reported (GAAP) | $ 6,664 | | $ 941 | | 14.1 % | 1) | | Specified items | 2,408 | | 329 | | | | | Excluding specified items | $ 9,072 | | $ 1,270 | | 14.0 % | | | | | | | | | | | | 12M22 | | | ($ in millions) | Pre-Tax Income | | Taxes on Earnings | | Tax Rate | | | As reported (GAAP) | $ 8,306 | | $ 1,373 | | 16.5 % | 2) | | Specified items | 2,924 | | 391 | | | | | Excluding specified items | $ 11,230 | | $ 1,764 | | 15.7 % | | | | | | 1) | 2023 Taxes on Earnings includes the recognition of approximately $22 million in excess tax benefits associated with share-based compensation. | | | | | 2) | 2022 Taxes on Earnings includes the recognition of approximately $43 million in excess tax benefits associated with share-based compensation. | | Abbott Laboratories and Subsidiaries Non-GAAP Revenue Reconciliation Fourth Quarter and Twelve Months Ended December 31, 2023 and 2022 ($ in millions) (unaudited) | | | | | | 4Q23 | | 4Q22 | | % Change vs. 4Q22 | | | | | | | | | | | | | | | Non-GAAP | | | | Abbott
Reported | Impact of CSI
acquisition (a) | Impact from
business exit (b) | Adjusted
Revenue | | Abbott
Reported | Impact from
business exit (b) | Adjusted
Revenue | | Reported | | Adjusted | Organic | | Total Company | | 10,241 | (40) | (7) | 10,194 | | 10,091 | (23) | 10,068 | | 1.5 | | 1.3 | 2.1 | | U.S. | | 3,949 | (38) | — | 3,911 | | 4,219 | — | 4,219 | | (6.4) | | (7.3) | (7.3) | | Intl | | 6,292 | (2) | (7) | 6,283 | | 5,872 | (23) | 5,849 | | 7.2 | | 7.4 | 8.8 | | | | | | | | | | | | | | | | | | Total Nutrition | | 2,038 | — | (7) | 2,031 | | 1,817 | (23) | 1,794 | | 12.2 | | 13.2 | 13.9 | | U.S. | | 860 | — | — | 860 | | 795 | — | 795 | | 8.2 | | 8.2 | 8.2 | | Intl | | 1,178 | — | (7) | 1,171 | | 1,022 | (23) | 999 | | 15.3 | | 17.2 | 18.5 | | | | | | | | | | | | | | | | | | Pediatric Nutrition | | 985 | — | (7) | 978 | | 882 | (23) | 859 | | 11.8 | | 14.0 | 14.5 | | U.S. | | 505 | — | — | 505 | | 454 | — | 454 | | 11.4 | | 11.4 | 11.4 | | Intl | | 480 | — | (7) | 473 | | 428 | (23) | 405 | | 12.3 | | 16.9 | 17.9 | | | | | | | | | | | | | | | | | | Total Medical Devices | | 4,443 | (40) | — | 4,403 | | 3,778 | — | 3,778 | | 17.5 | | 16.4 | 15.4 | | U.S. | | 2,065 | (38) | — | 2,027 | | 1,754 | — | 1,754 | | 17.6 | | 15.5 | 15.5 | | Intl | | 2,378 | (2) | — | 2,376 | | 2,024 | — | 2,024 | | 17.5 | | 17.4 | 15.4 | | | | | | | | | | | | | | | | | | Vascular | | 677 | (40) | — | 637 | | 605 | — | 605 | | 12.0 | | 5.6 | 4.5 | | U.S. | | 245 | (38) | — | 207 | | 214 | — | 214 | | 14.8 | | (2.5) | (2.5) | | Intl | | 432 | (2) | — | 430 | | 391 | — | 391 | | 10.4 | | 9.9 | 8.3 | | | 12M23 | | 12M22 | | % Change vs. 12M22 | | | | | | | | | | | | | Non-GAAP | | | Abbott
Reported | Impact of CSI
acquisition (a) | Impact from
business exit (b) | Adjusted
Revenue | | Abbott
Reported | Impact from
business exit (b) | Adjusted
Revenue | | Reported | Adjusted | Organic | | Total Company | 40,109 | (130) | (48) | 39,931 | | 43,653 | (135) | 43,518 | | (8.1) | (8.2) | (6.2) | | U.S. | 15,452 | (123) | — | 15,329 | | 18,142 | — | 18,142 | | (14.8) | (15.5) | (15.5) | | Intl | 24,657 | (7) | (48) | 24,602 | | 25,511 | (135) | 25,376 | | (3.3) | (3.0) | 0.5 | | | | | | | | | | | | | | | | Total Nutrition | 8,154 | — | (48) | 8,106 | | 7,459 | (135) | 7,324 | | 9.3 | 10.7 | 13.0 | | U.S. | 3,413 | — | — | 3,413 | | 2,919 | — | 2,919 | | 16.9 | 16.9 | 16.9 | | Intl | 4,741 | — | (48) | 4,693 | | 4,540 | (135) | 4,405 | | 4.4 | 6.6 | 10.4 | | | | | | | | | | | | | | | | Pediatric Nutrition | 3,934 | — | (48) | 3,886 | | 3,481 | (135) | 3,346 | | 13.0 | 16.1 | 17.9 | | U.S. | 1,977 | — | — | 1,977 | | 1,562 | — | 1,562 | | 26.6 | 26.6 | 26.6 | | Intl | 1,957 | — | (48) | 1,909 | | 1,919 | (135) | 1,784 | | 2.0 | 7.1 | 10.3 | | | | | | | | | | | | | | | | Total Medical Devices | 16,887 | (130) | — | 16,757 | | 14,802 | — | 14,802 | | 14.1 | 13.2 | 14.2 | | U.S. | 7,696 | (123) | — | 7,573 | | 6,681 | — | 6,681 | | 15.2 | 13.3 | 13.3 | | Intl | 9,191 | (7) | — | 9,184 | | 8,121 | — | 8,121 | | 13.2 | 13.1 | 14.9 | | | | | | | | | | | | | | | | Vascular | 2,681 | (130) | — | 2,551 | | 2,483 | — | 2,483 | | 8.0 | 2.7 | 4.0 | | U.S. | 978 | (123) | — | 855 | | 864 | — | 864 | | 13.2 | (1.0) | (1.0) | | Intl | 1,703 | (7) | — | 1,696 | | 1,619 | — | 1,619 | | 5.2 | 4.7 | 6.7 | | | | | (a) | Reflects the impact of the acquisition of Cardiovascular Systems, Inc. (CSI) on April 27, 2023. | | (b) | Reflects the impact of exiting the pediatric nutrition business in China. This action was initiated in December 2022. | | Abbott Laboratories and Subsidiaries Details of Specified Items Fourth Quarter Ended December 31, 2023 (in millions, except per share data) (unaudited) | | | | | Acquisition or Divestiture- related (a) | | Restructuring and Cost Reduction Initiatives (b) | | Intangible Amortization | | Other (c) | | Total Specifieds | | Gross Margin | $ 1 | | $ 29 | | $ 481 | | $ 7 | | $ 518 | | R&D | (6) | | (4) | | — | | (68) | | (78) | | SG&A | (15) | | (5) | | — | | (15) | | (35) | | Other (income) expense, net | (6) | | — | | — | | (3) | | (9) | | Earnings before taxes | $ 28 | | $ 38 | | $ 481 | | $ 93 | | 640 | | Taxes on Earnings (d) | | | | | | | | | 140 | | Net Earnings | | | | | | | | | $ 500 | | Diluted Earnings per Share | | | | | | | | | $ 0.28 | | | | | The table above provides additional details regarding the specified items described on tables titled “Non-GAAP Reconciliation of Financial Information.” | | | | | a) | Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses, as well as legal and other costs related to business acquisitions. | | b) | Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives. | | c) | Other includes incremental costs to comply with the European Union’s Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products and charges for intangible asset impairments. | | d) | Reflects the net tax benefit associated with the specified items. | | Abbott Laboratories and Subsidiaries Details of Specified Items Fourth Quarter Ended December 31, 2022 (in millions, except per share data) (unaudited) | | | | | Acquisition or Divestiture- related (a) | | Restructuring and Cost Reduction Initiatives (b) | | Intangible Amortization | | Other (c) | | Total Specifieds | | Gross Margin | $ 23 | | $ 87 | | $ 496 | | $ 6 | | $ 612 | | R&D | (6) | | (34) | | — | | (31) | | (71) | | SG&A | (7) | | (135) | | — | | (2) | | (144) | | Other (income) expense, net | 3 | | — | | — | | (27) | | (24) | | Earnings before taxes | $ 33 | | $ 256 | | $ 496 | | $ 66 | | 851 | | Taxes on Earnings (d) | | | | | | | | | 73 | | Net Earnings | | | | | | | | | $ 778 | | Diluted Earnings per Share | | | | | | | | | $ 0.44 | | | | | The table above provides additional details regarding the specified items described on tables titled “Non-GAAP Reconciliation of Financial Information.” | | a) | Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating the acquired businesses and include expenditures for the integration of systems, processes and business activities. | | | | | b) | Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives. | | | | | c) | Other includes incremental costs to comply with the European Union’s Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products as well as the impairment of an equity investment. | | d) | Reflects the net tax benefit associated with the specified items. | | Abbott Laboratories and Subsidiaries Details of Specified Items Twelve Months Ended December 31, 2023 (in millions, except per share data) (unaudited) | | | | | Acquisition or Divestiture- related (a) | | Restructuring and Cost Reduction Initiatives (b) | | Intangible Amortization | | Other (c) | | Total Specifieds | | Gross Margin | $ 16 | | $ 80 | | $ 1,966 | | $ 47 | | $ 2,109 | | R&D | (19) | | (9) | | — | | (194) | | (222) | | SG&A | (58) | | (33) | | — | | (11) | | (102) | | Other (income) expense, net | 40 | | — | | — | | (15) | | 25 | | Earnings before taxes | $ 53 | | $ 122 | | $ 1,966 | | $ 267 | | 2,408 | | Taxes on Earnings (d) | | | | | | | | | 329 | | Net Earnings | | | | | | | | | $ 2,079 | | Diluted Earnings per Share | | | | | | | | | $ 1.18 | | | | | The table above provides additional details regarding the specified items described on tables titled “Non-GAAP Reconciliation of Financial Information.” | | | | | a) | Acquisition-related expenses include legal and other costs related to business acquisitions as well as integration costs, which represent incremental costs directly related to integrating acquired businesses. | | b) | Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives. | | c) | Other includes incremental costs to comply with the MDR and IVDR regulations for previously approved products and charges for intangible asset impairments. | | d) | Reflects the net tax benefit associated with the specified items. | | Abbott Laboratories and Subsidiaries Details of Specified Items Twelve Months Ended December 31, 2022 (in millions, except per share data) (unaudited) | | | | | Acquisition or Divestiture- related (a) | | Restructuring and Cost Reduction Initiatives (b) | | Intangible Amortization | | Other (c) | | Total Specifieds | | Gross Margin | $ 79 | | $ 86 | | $ 2,013 | | $ 173 | | $ 2,351 | | R&D | (16) | | (38) | | — | | (228) | | (282) | | SG&A | (38) | | (140) | | — | | (58) | | (236) | | Other (income) expense, net | (12) | | — | | — | | (43) | | (55) | | Earnings before taxes | $ 145 | | $ 264 | | $ 2,013 | | $ 502 | | 2,924 | | Taxes on Earnings (d) | | | | | | | | | 391 | | Net Earnings | | | | | | | | | $ 2,533 | | Diluted Earnings per Share | | | | | | | | | $ 1.43 | | | | | The table above provides additional details regarding the specified items described on tables titled “Non-GAAP Reconciliation of Financial Information.” | | a) | Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating the acquired businesses and include expenditures for the integration of systems, processes and business activities. | | b) | Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives. The Gross Margin amount includes a credit associated with the charges taken in the second quarter of 2021 for a restructuring plan related to Abbott’s manufacturing network for COVID-19 diagnostic tests. | | c) | Other primarily relates to the net costs related to a voluntary recall within the Nutrition segment, charges associated with the impairments of R&D intangible assets and an equity investment acquired in a business combination, incremental costs to comply with the European Union’s MDR and IVDR Regulations for previously approved products and costs related to certain litigation. | | d) | Reflects the net tax benefit associated with the specified items, excess tax benefits associated with share-based compensation and net tax expense as a result of the resolution of various tax positions related to prior years. |  View original content:https://www.prnewswire.com/news-releases/abbott-reports-fourth-quarter-and-full-year-2023-results-issues-2024-financial-outlook-302043275.html
SOURCE Abbott | |
